Picard Medical Announces Conference Participation During J.P. Morgan Healthcare Conference Week

Picard Medical (NYSE American: PMI) announced its management team will attend conferences during the week of the 44th Annual J.P.

Rhea-AI Summary

Picard Medical (NYSE American: PMI) announced its management team will attend conferences during the week of the 44th Annual J.P. Morgan Healthcare Conference (JPM week) in San Francisco.

Planned appearances include an invite-only Lifeblood and Goodwin MedTech CEO-Only Forum on January 12, 2026 at the InterContinental, and one-on-one meetings at the LifeSci Advisors 15th Annual Corporate Access Event on January 14, 2026 at The Beacon Grand. Investors may request in-person meetings via LifeSci registration or by contacting the LifeSci representative Eric Ribner at eric@lifesciadvisors.com.

Argus Jan 7 session

+10.40% close to close Open Argus

Details

News Market Reaction – PMI

On Jan 7, the day this news came out, PMI closed 10.40% above the previous close.

Data tracked by StockTitan Argus for the Jan 7 session.

Key Figures

JPM healthcare week: 44th Annual MedTech CEO forum date: January 12, 2026 Corporate access date: January 14, 2026

JPM healthcare week

44th Annual

Week of the 44th Annual J.P. Morgan Healthcare Conference

MedTech CEO forum date

January 12, 2026

Lifeblood and Goodwin’s MedTech CEO-Only Forum

Corporate access date

January 14, 2026

LifeSci Advisors 15th Annual Corporate Access Event

Historical Context

5 past events · Latest: Dec 30

5 events

1. Dec 30

   Management/board update

   24h Move

   -6.4%

   CEO elected to Arizona Bioindustry Association board through December 2028.

2. Dec 24

   Debt financing

   24h Move

   -1.9%

   Announcement of up to $50M senior secured notes and warrants for funding.

3. Dec 18

   Listing milestone

   24h Move

   +10.3%

   Company marked NYSE opening bell to highlight transition to public markets.

4. Dec 09

   Clinical durability update

   24h Move

   -8.7%

   Patient surpassed 2,900 days supported by SynCardia Total Artificial Heart.

5. Dec 03

   Conference presentation

   24h Move

   +2.0%

   CEO scheduled to present Emperor Total Artificial Heart data at CSI Focus D-HF.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

total artificial heart, u.s. food and drug administration, fda, health canada

4 terms

total artificial heart medical

"maker of the world’s first total artificial heart approved by both the U.S."

A total artificial heart is a surgically implanted mechanical device that replaces the heart’s two main pumping chambers and takes over circulation, acting like a continuous pump that keeps blood moving through the body. Investors care because it is a high-cost, high-stakes medical product whose commercial success depends on clinical trial results, regulatory approvals, hospital adoption, reimbursement rules and long-term patient outcomes — factors that drive revenue potential and risk.

u.s. food and drug administration regulatory

"artificial heart approved by both the U.S. Food and Drug Administration (FDA) and"

The U.S. Food and Drug Administration is the federal agency that evaluates and enforces safety, effectiveness and labeling standards for medicines, medical devices, vaccines, food and related products before they reach consumers. For investors it matters because FDA approvals, warnings or recalls determine whether a product can be sold, how quickly it reaches the market and how costly compliance will be—changes that directly affect a company’s revenue, costs and stock value.

fda regulatory

"artificial heart approved by both the U.S. Food and Drug Administration (FDA) and"

The FDA is the U.S. federal agency that evaluates and approves medical drugs, devices, biological therapies and certain foods; think of it as the gatekeeper that decides whether a medical product is safe and effective for patients. For investors, FDA decisions determine whether a company can sell a product, affect expected revenue and introduce regulatory risk, so approvals, rejections or safety warnings can quickly move a company's valuation and stock price.

health canada regulatory

"approved by both the U.S. Food and Drug Administration (FDA) and Health Canada today"

Health Canada is the government department responsible for overseeing the safety and regulation of health-related products and services in Canada, including medications, medical devices, and vaccines. Its approval and guidelines help ensure that these products are safe and effective for public use. For investors, Health Canada's decisions can influence the success of healthcare companies and affect the availability of new medical treatments in the Canadian market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

TUCSON, Ariz., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems, LLC, maker of the world’s first total artificial heart approved by both the U.S. Food and Drug Administration (FDA) and Health Canada today announced that today announced its attendance at conferences during the week of the 44^th Annual J.P. Morgan Healthcare Conference (“JPM week”) including at LifeSci Advisors’ Corporate Access Event and Lifeblood and Goodwin’s CEO-Only MedTech Forum.

Information on both events is below.

Lifeblood and Goodwin’s MedTech CEO-Only Forum
Date: January 12, 2026
Format: Invite-only discussion forum
Location: InterContinental, San Francisco, CA

LifeSci Advisors 15^th Annual Corporate Access Event
Date: January 14, 2026
Format: One-on-one meetings
Location: The Beacon Grand, San Francisco, CA

To request an in-person meeting with the Picard Medical management team on Wednesday January 14^th, either register at LifeSci Partners Corporate Access Event 2026 or contact our LifeSci Partners representative Eric Ribner (eric@lifesciadvisors.com).

About Picard Medical, Inc.
Picard Medical, Inc. is the parent company of SynCardia Systems, LLC (“SynCardia”), the Tucson, Arizona–based leader with the only commercially available total artificial heart technology for patients with end-stage heart failure. SynCardia develops, manufactures, and commercializes the SynCardia Total Artificial Heart (“STAH”), an implantable system that assumes the full functions of a failing or failed human heart. It is the first artificial heart approved by both the FDA and Health Canada, and it remains the only commercially available artificial heart in the United States and Canada. With more than 2,100 implants performed at hospitals across 27 countries, the SynCardia Total Artificial Heart is the most widely used and extensively studied artificial heart in the world. For more information, please visit https://www.syncardia.com.

Forward-Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Contact:

Investors
Eric Ribner
Managing Director
LifeSci Advisors LLC
eric@lifesciadvisors.com

Picard Medical, Inc./SynCardia Systems, LLC
IR@picardmedical.com

General/Media
Brittany Lanza
blanza@syncardia.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Picard Medical (PMI) attend JPM week events in 2026?

Picard Medical indicated management will attend events during JPM week, including January 12 and January 14, 2026.

Which Picard Medical events are scheduled for January 12 and January 14, 2026?

An invite-only Lifeblood and Goodwin MedTech CEO-Only Forum on January 12, 2026, and LifeSci Advisors one-on-one meetings on January 14, 2026.

Where will Picard Medical meet investors during JPM week 2026?

The January 12 forum is at the InterContinental, San Francisco, and January 14 meetings are at The Beacon Grand, San Francisco.

How can investors request an in-person meeting with Picard Medical (PMI) on January 14, 2026?

Register at the LifeSci Partners Corporate Access Event 2026 or contact LifeSci representative Eric Ribner at eric@lifesciadvisors.com.

Is the Picard Medical JPM week participation open to the public?

The MedTech CEO-Only Forum on January 12 is invite-only; the January 14 LifeSci meetings are scheduled as one-on-one sessions requiring registration or a contact.